JAMA Cardiology Submission Process

The process usually feels cleaner when the manuscript already arrives with:

• a broad-enough cardiology audience case
• a practice-facing consequence that is visible early
• methods and statistics stable enough for editorial and statistical scrutiny
• complete registration, reporting, ethics, and disclosure materials

If those pieces are soft, the workflow can feel harsher than authors expect because the system exposes weakness early.

The current official numbers reinforce that point. With 9% overall acceptance and 6% research acceptance, the process is built to say no quickly when the journal does not see broad clinical cardiology value.

The JAMA Cardiology drafts that hold up best are the ones where the clinical consequence is visible immediately and the methods already look publication-ready under a hard editorial read. The weak drafts often have interesting cardiology results, but the package still feels too specialist, too locally framed, or too dependent on the cover letter to explain why the paper matters outside one niche.

The first stage is not only testing whether the study is interesting.

It is testing whether:

• the paper matters to broad cardiovascular practice
• the methods can survive early statistical scrutiny
• the package looks stable enough to justify reviewer time
• the manuscript was actually prepared for JAMA Cardiology's readership
• the paper deserves flagship JAMA Network cardiology attention rather than referral elsewhere

That is why fast rejection here often means "not broad or mature enough for this journal," not "bad science."

Authors should think in stages:

• the earliest period is mostly audience-fit, reporting discipline, and methodological screening
• movement into full review usually means the hardest broad-clinical screen has been cleared
• later slowdowns often reflect reviewer matching, stats questions, or interpretation scope rather than admin delay

The practical point is that the real risk sits early. Once the paper survives that first editorial and statistical pass, the process becomes more about evidentiary debate than venue fit.

JAMA Cardiology inherits JAMA Network's strict formatting requirements. This is more demanding than JACC or EHJ at initial submission.

Required materials:

• manuscript in AMA citation format with JAMA-style structured abstract (Importance, Objective, Design/Setting/Participants, etc.)
• all figures and tables as separate files
• ICMJE conflict of interest forms for every author
• fully completed reporting checklist (CONSORT, STROBE, PRISMA, etc.)
• trial registration number (mandatory for interventional studies)
• data sharing statement
• IRB/ethics documentation

The structured abstract with the "Importance" section is inherited from JAMA. Many cardiology researchers coming from JACC (which uses a simpler Background/Methods/Results/Conclusions format) forget to include it. The Importance section should state why this cardiovascular question matters to clinical practice, not summarize what was previously known.

Before you upload, run through JAMA Cardiology submission readiness check to catch formatting and structural issues early.

JAMA Cardiology's editorial filter differs from its competitors in specific ways:

1. Methodology gets more scrutiny here than at JACC. The in-house statistical review means that underpowered studies, post-hoc analyses presented as primary endpoints, and trials with significant protocol deviations face a harder screen. If your trial has known statistical weaknesses, JACC may be more forgiving.

2. Cross-specialty relevance is weighted more heavily. JAMA Cardiology wants papers that matter to internists and primary care physicians, not just cardiologists. A paper about a new interventional technique that only interventional cardiologists would implement may fit better at JACC. A paper about cardiovascular risk screening that primary care doctors would order fits naturally at JAMA Cardiology.

3. Health equity and disparities content is welcomed. JAMA Network has invested in publishing disparities research. If your cardiovascular study addresses racial, socioeconomic, or geographic disparities, lean into that angle in the cover letter.

4. Imaging and biomarker studies face a higher bar. JAMA Cardiology publishes these, but only when the clinical utility is demonstrated, not just the diagnostic accuracy. A study showing that a new biomarker predicts outcomes better than existing markers needs to also show that it would change clinical decisions.

5. Transfer logic is part of the real workflow. The brochure explicitly says papers not accepted by JAMA Cardiology may be referred, with reviews, to another JAMA Network specialty journal or JAMA Network Open. Authors should think about that path before submission, not only after rejection.

Several things repeatedly make the process go badly:

The science may be strong, but if the natural readers are mainly one subspecialty, editors often see that quickly.

JAMA Cardiology does not give much patience to papers that look underpowered, too local, or analytically fragile on first inspection.

Editors do not reward bigger language unless the paper can support it. Overclaiming usually damages trust faster than it helps.

If the abstract, early results, and first table or figure do not make the cardiovascular importance obvious, the editor has less reason to keep carrying the paper forward.

The strongest JAMA Cardiology submissions usually have a recognizable profile:

• one clinically important cardiovascular question
• one stable main conclusion
• one audience case that makes sense for broad cardiology readers
• one first-read package that feels methodologically sound
• one cover letter that sounds like judgment, not marketing

This is why the process is not just administrative. The package itself tells the editor whether the authors understand the journal.

One common failure mode is a letter that promises a broader or more practice-changing paper than the manuscript actually delivers. Editors usually catch that mismatch immediately.

If the key clinical message takes too long to emerge, the editor may conclude the paper is too slow for a broad cardiology audience even if the study is strong.

A JAMA Cardiology submission loses force when the title, abstract, declarations, and supporting material still look provisional. Package instability often gets interpreted as scientific or strategic instability.

Some papers are good enough for the network but not for this title. When that happens, the process often becomes a fit or transfer conversation rather than a debate about whether the science is valid.

The abstract and cover letter should reinforce each other.

The abstract should:

• state the central finding plainly
• make the clinical consequence visible
• avoid overselling before the evidence can support the promise

The cover letter should:

• explain why cardiology readers should care
• clarify what decision or practice implication changes
• give the editor a clean reason to send the paper out

If those two pieces describe different levels of ambition, the package weakens immediately.

The final hour before a serious JAMA Cardiology submission should not be spent rewriting the science. It should be spent making sure the package is internally consistent.

That usually means checking:

• the title, abstract, and cover letter all make the same practical claim
• the key table or figure supports the same claim the abstract is making
• ethics language, disclosures, and registration details match the manuscript exactly
• supplementary materials do not introduce contradictions or unexplained analyses
• author order and affiliations are final

If those pieces still feel fluid, the submission often looks less mature than the science deserves.

• the paper already looks broad enough for cardiology practice
• the methodology is stable enough to survive hard review
• the practical consequence is visible from the first read
• the package looks publication-ready

• the study still needs obvious analytical strengthening
• the broad cardiology case depends more on language than data
• the package is still being assembled during upload
• a narrower cardiology journal still looks like the more honest home

This is one of the fastest ways to weaken trust. The problem is not only overclaiming. It is making the first read unstable.

Editors need a reason the paper belongs in JAMA Cardiology. A letter that mainly says the work is exciting or high impact without explaining the audience case is usually weaker than authors think.

A submission can satisfy the portal while still looking conceptually unsettled. If the package logic still feels provisional, the process weakens before review starts.

• JAMA Cardiology journal page
• JAMA Cardiology Submission Guide
• Is JAMA Cardiology a Good Journal?
• How to Avoid Desk Rejection at JAMA Oncology
• JACC Submission Process